Latest

19:54
【HAIXI PHARMA (02637.HK): HX9428 for Neovascular Age-Related Macular Degeneration Granted Fast Track Designation by US FDA】NewTimeSpace News: On 17 August 2026, HAIXI PHARMA (02637.HK) announced that its self-developed oral small-molecule innovative drug HX9428 has been granted Fast Track Designation by the US FDA for the treatment of neovascular age-related macular degeneration (nAMD); HX9428 has completed Phase I clinical studies, is advancing Phase II studies, and has received FDA approval to conduct a Phase II clinical trial in the United States.
Tag： HAIXI PHARMA02637.HKResearch Progress
19:42
【HANXBIO-B(03378.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 36.88 million, loss widened by 1.22% YoY】August 17, 2026, HANXBIO-B(03378.HK) released its Interim Report for the period ended December 31, 2026
Tag： HANXBIO-B03378.HK
19:42
【BILLION IND(02299.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 985.32 million, YoY increase of 161.57%】August 17, 2026, BILLION IND(02299.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 12.71 billion, increased by 34.03% YoY
Tag： BILLION IND02299.HK
19:41
【ZHIDA TECH(02650.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 116.61 million, loss widened by 288.46% YoY】August 17, 2026, ZHIDA TECH(02650.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 340.32 million, decreased by 13.33% YoY
Tag： ZHIDA TECH02650.HK
19:41
【STAR SPORTS MED(01609.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 27.4 million, YoY decrease of 26.12%】August 17, 2026, STAR SPORTS MED(01609.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 163.43 million, increased by 21.62% YoY
Tag： STAR SPORTS MED01609.HK
19:41
【COWELL(01415.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 89.87 million, YoY increase of 33.35%】August 17, 2026, COWELL(01415.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 1.6 billion, increased by 17.97% YoY
Tag： COWELL01415.HK
19:41
【CONANT OPTICAL(02276.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 301.18 million, YoY increase of 10.38%】August 17, 2026, CONANT OPTICAL(02276.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.17 billion, increased by 7.64% YoY
Tag： CONANT OPTICAL02276.HK
19:34
【HWORLD-S(01179.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.39 billion, YoY decrease of 1.8%】August 17, 2026, HWORLD-S(01179.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 13.12 billion, increased by 10.96% YoY
Tag： HWORLD-S01179.HK
19:34
【GUOQUAN(02517.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 211.25 million, YoY increase of 15.22%】August 17, 2026, GUOQUAN(02517.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 3.95 billion, increased by 21.83% YoY
Tag： GUOQUAN02517.HK
19:25
【MICOT PHARMA-B (02335.HK): Three XTL6001 Studies Accepted for Presentation at EASD 2026 and ASN Kidney Week 2026, Triple-Agonist Mechanism Gains International Recognition】NewTimeSpace News: On 17 August 2026, MICOT PHARMA-B (02335.HK) announced that three studies on its key product XTL6001 have been accepted for presentation at international academic conferences: two abstracts were accepted at EASD 2026 (including an oral presentation and a short oral discussion) and one at ASN Kidney Week 2026 as a poster; XTL6001 is a GLP-1R/GCGR/MasR triple-target agonist approved for clinical studies in both China and the US, being developed for weight management, proteinuric CKD and MASH.
Tag： Micot Pharma-B02335.HKResearch Progress
19:21
【GOLDENPOWER (03919.HK): Subscription of 6.49 Million New Shares Completed, Subscriber to Become Substantial Shareholder with 14.3%】NewTimeSpace News: On 17 August 2026, GOLDENPOWER (03919.HK) announced the completion of the subscription of new shares under the general mandate, with 6,492,000 subscription shares allotted and issued at HKD 0.65 per share, representing approximately 14.3% of the enlarged issued share capital, and the subscriber becoming a substantial shareholder; net proceeds of approximately HKD 4.1 million will be used mainly to repay due bank facilities.
Tag： GOLDENPOWER03919.HKSubscription
19:16
【CCT FORTIS (00138.HK): Expects H1 Net Loss to Narrow to HKD 120-140 Million on Lower Property Impairment and Administrative Expenses】NewTimeSpace News: On 17 August 2026, CCT FORTIS (00138.HK) issued a profit warning, expecting a consolidated net loss attributable to owners of the company of between approximately HKD 120 million and HKD 140 million for the six months ended 30 June 2026, narrowing from approximately HKD 210 million in the same period of 2025, mainly due to a decrease of approximately HKD 73 million in property impairment losses and approximately HKD 22 million in administrative expenses following a subsidiary disposal.
Tag： CCT FORTIS00138.HKProfit Warning
18:37
【SINOPEC CORP(00386.HK) will spend CNY 6.5 million to repurchase 1.3 million shares on Aug 17, 2026】SINOPEC CORP(00386.HK) will spend CNY 6.5 million to repurchase 1.3 million shares on Aug 17, 2026 .
Tag： SINOPEC CORP00386.HK
18:37
【MIDEA GROUP(00300.HK) will spend CNY 110.21 million to repurchase 1.33 million shares on Aug 17, 2026】MIDEA GROUP(00300.HK) will spend CNY 110.21 million to repurchase 1.33 million shares on Aug 17, 2026 .
Tag： MIDEA GROUP00300.HK
18:37
【SEER TECH(06106.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 37.89 million, loss narrowed by 25.1% YoY】August 17, 2026, SEER TECH(06106.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 264.39 million, increased by 67.49% YoY
Tag： SEER TECH06106.HK
18:37
【TE HEALTHCARE(06877.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 1.37 million, turned profitable from a loss YoY】August 17, 2026, TE HEALTHCARE(06877.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 74.51 million, increased by 64.89% YoY
Tag： TE HEALTHCARE06877.HK
18:37
【HISENSE HA(00921.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.66 billion, YoY decrease of 20.16%】August 17, 2026, HISENSE HA(00921.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 46.77 billion, decreased by 5.22% YoY
Tag： HISENSE HA00921.HK
18:21
【HASHKEY HLDGS(03887.HK) closed 12.15% higher, the Hang Seng Other Financials Sector saw divergent trends】By the close of trading on Aug 17, 2026, HASHKEY HLDGS(03887.HK) saw a gain of 12.15% in its share price, closing at HKD 2.815. During the session, it reached an intraday high of HKD 2.82 and touched an intraday low of HKD 2.51.
Tag： HashKey HLDGS03887.HK
18:21
【CHERVON(02285.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 106.28 million, YoY increase of 11.62%】August 17, 2026, CHERVON(02285.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 1.03 billion, increased by 12.78% YoY
Tag： CHERVON02285.HK
18:21
【GUOTAI JUNAN I(01788.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 674.86 million, YoY increase of 22.68%】August 17, 2026, GUOTAI JUNAN I(01788.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 3.87 billion, increased by 37.02% YoY
Tag： GUOTAI JUNAN I01788.HK
Previous1..6970 717273..488     488 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments